Related Experiment Video
Updated: Nov 18, 2025

Noninvasive and Invasive Renal Hypoxia Monitoring in a Porcine Model of Hemorrhagic Shock
Published on: October 28, 2022
Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors
Clara García-Carro1, Mónica Bolufer1, Roxana Bury1
1Nephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, Barcelona, Spain.
Background:
Checkpoint inhibitors (CPIs) have drastically improved metastatic cancer outcomes. However, immunotherapy is associated with multiple toxicities, including acute kidney injury (AKI). Data about CPI-related AKI are limited. Our aim was to determine risk factors for CPI-related AKI as well as its clinical characteristics and its impact on mortality in patients undergoing immunotherapy.
Methods:
All patients under CPI at our centre between March 2018 and May 2019 and with a follow-up through April 2020 were included. Demographic, clinical and laboratory data were collected. AKI was defined according to the Kidney Disease: Improving Global Outcomes guidelines. We performed a logistic regression model to identify independent risk factors for AKI and actuarial survival analysis to establish risk factors for mortality in this population.
Results:
A total of 759 patients were included, with a median age of 64 years. A total of 59% were men and baseline median creatinine was 0.80 mg/dL. The most frequent malignancy was lung cancer and 56% were receiving anti-programmed death protein 1 (PD-1). About 15.5% developed AKI during the follow-up. Age and baseline kidney function were identified as independent risk factors for CPI-related AKI. At the end of follow-up, 52.3% of patients had died. The type of cancer (not melanoma, lung or urogenital malignance), type of CPI (not cytotoxic T-lymphocyte-associated protein 4, PD-1, programmed death-ligand 1 or their combination) and the presence of an episode of AKI were identified as risk factors for mortality.
Conclusions:
A total of 15.5% of patients under immunotherapy presented with AKI. A single AKI episode was identified as an independent risk factor for mortality in these patients and age and baseline renal function were risk factors for the development of AKI.
Insights
Checkpoint inhibitors (CPIs) improve cancer outcomes but can cause acute kidney injury (AKI). Age and baseline kidney function predict AKI development, and AKI increases mortality risk in immunotherapy patients.
Area of Science:
- Oncology
- Nephrology
- Immunology
Background:
- Checkpoint inhibitors (CPIs) have revolutionized metastatic cancer treatment.
- Immunotherapy with CPIs is linked to toxicities, notably acute kidney injury (AKI).
- Limited data exist on CPI-related AKI risk factors, clinical features, and mortality impact.
Purpose of the Study:
- To identify risk factors for CPI-related AKI.
- To characterize the clinical presentation of CPI-related AKI.
- To determine the impact of CPI-related AKI on patient mortality.
Main Methods:
- Retrospective analysis of 759 patients receiving CPIs between March 2018 and April 2020.
- Data collection included demographics, clinical details, and laboratory values.
- AKI diagnosis followed KDIGO guidelines; logistic regression and survival analysis were used.
Main Results:
- 15.5% of patients developed AKI.
- Independent risk factors for AKI included older age and poorer baseline kidney function.
- Mortality risk was associated with specific cancer types, CPI types, and the occurrence of AKI.
Conclusions:
- Age and baseline renal function are key predictors of CPI-related AKI.
- A single episode of AKI independently elevates mortality risk in patients undergoing immunotherapy.
- Understanding these factors is crucial for managing immunotherapy-related toxicities.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury III: Clinical Manifestations
Kidney Transplant III: Nursing Management
Acute Kidney Injury VI: Nursing Management

